Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Tempest Therapeutics (NASDAQ:TPSTFree Report) in a research note issued to investors on Thursday, Benzinga reports. HC Wainwright currently has a $47.00 price objective on the stock.

A number of other brokerages also recently commented on TPST. William Blair reaffirmed an outperform rating on shares of Tempest Therapeutics in a research report on Wednesday, March 20th. Scotiabank started coverage on shares of Tempest Therapeutics in a research report on Thursday, March 14th. They set a sector outperform rating and a $13.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of Buy and an average price target of $20.75.

Read Our Latest Analysis on Tempest Therapeutics

Tempest Therapeutics Stock Performance

Tempest Therapeutics stock opened at $2.03 on Thursday. The firm’s 50 day simple moving average is $3.24 and its 200-day simple moving average is $3.70. The company has a market cap of $45.11 million, a P/E ratio of -1.18 and a beta of -1.78. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.13 and a quick ratio of 3.13. Tempest Therapeutics has a fifty-two week low of $0.17 and a fifty-two week high of $9.77.

Tempest Therapeutics (NASDAQ:TPSTGet Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.08. As a group, equities research analysts predict that Tempest Therapeutics will post -1.58 EPS for the current year.

Institutional Trading of Tempest Therapeutics

An institutional investor recently bought a new position in Tempest Therapeutics stock. MayTech Global Investments LLC bought a new position in Tempest Therapeutics, Inc. (NASDAQ:TPSTFree Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $44,000. Tempest Therapeutics makes up about 0.0% of MayTech Global Investments LLC’s portfolio, making the stock its 29th largest holding. MayTech Global Investments LLC owned 0.05% of Tempest Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

(Get Free Report)

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.

See Also

Analyst Recommendations for Tempest Therapeutics (NASDAQ:TPST)

Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.